Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study

Raghu, Ganesh; Blink, Bernt van den; Hamblin, Mark J.; Brown, Anne; Golden, Jeffrey A.; Ho, Lawrence; Wijsenbeek, Marlies; Vašáková, Martina; Pesci, Alberto; Antin‐Ozerkis, Danielle; Meyer, Keith C.; Kreuter, Michael; Moran, D.G.; Santin-Janin, Hugues; Aubin, F.; Mulder, G.-J.J.; Gupta, Renu; Richeldi, Luca

doi:10.1016/s2213-2600(19)30172-9

Cited by 83 publications

(61 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Namely, in the field of ILDs, AI can help to differentiate and early diagnose the patients with the most severe forms, i.e., IPF. Early diagnosis in IPF will lead to targeted antifibrotic treatment which substantially prolongs the survival and reduces acute exacerbations which are not only deadly but also costly [52][53][54][55][56]. In order to reach such high expectations, a hybrid algorithm should be developed.…”

Section: Discussionmentioning

confidence: 99%

Deep learning in interstitial lung disease—how long until daily practice

et al. 2020

View full text Add to dashboard Cite

Interstitial lung diseases are a diverse group of disorders that involve inflammation and fibrosis of interstitium, with clinical, radiological, and pathological overlapping features. These are an important cause of morbidity and mortality among lung diseases. This review describes computer-aided diagnosis systems centered on deep learning approaches that improve the diagnostic of interstitial lung diseases. We highlighted the challenges and the implementation of important daily practice, especially in the early diagnosis of idiopathic pulmonary fibrosis (IPF). Developing a convolutional neuronal network (CNN) that could be deployed on any computer station and be accessible to non-academic centers is the next frontier that needs to be crossed. In the future, early diagnosis of IPF should be possible. CNN might not only spare the human resources but also will reduce the costs spent on all the social and healthcare aspects of this deadly disease. Key Points • Deep learning algorithms are used in pattern recognition of different interstitial lung diseases. • High-resolution computed tomography plays a central role in the diagnosis and in the management of all interstitial lung diseases, especially fibrotic lung disease. • Developing an accessible algorithm that could be deployed on any computer station and be used in non-academic centers is the next frontier in the early diagnosis of idiopathic pulmonary fibrosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Deep learning in interstitial lung disease—how long until daily practice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Patients with IPF showed significantly reduced plasma levels of pentraxin 2, which was correlated with disease severities [ 166 ]. Recent studies have reported that a recombinant human pentraxin 2, named PRM-151, is well tolerated and slows the decline of lung function in IPF patients, suggesting that modulation of macrophages differentiation and activation may serve as potential therapies for treating lung fibrosis in the future [ 167 , 168 ].…”

Section: Current Progress On Immune-based Anti-fibrotic Therapiesmentioning

confidence: 99%

The Roles of Immune Cells in the Pathogenesis of Fibrosis

Huang

Peng

Xiao

et al. 2020

IJMS

View full text Add to dashboard Cite

Tissue injury and inflammatory response trigger the development of fibrosis in various diseases. It has been recognized that both innate and adaptive immune cells are important players with multifaceted functions in fibrogenesis. The activated immune cells produce various cytokines, modulate the differentiation and functions of myofibroblasts via diverse molecular mechanisms, and regulate fibrotic development. The immune cells exhibit differential functions during different stages of fibrotic diseases. In this review, we summarized recent advances in understanding the roles of immune cells in regulating fibrotic development and immune-based therapies in different disorders and discuss the underlying molecular mechanisms with a focus on mTOR and JAK-STAT signaling pathways.

show abstract

“…These preclinical results paved the way to clinical development of SAP (PRM-151) as an anti-fibrotic agent 34 , 35 . Early Phase II results of PRM-151 in idiopathic pulmonary fibrosis are encouraging 36 , 37 . Current therapeutic limitations as well as concerns over the emergence of antifungal resistance are inspiring the search for novel host-directed therapies.…”

Section: Discussionmentioning

confidence: 99%

“…In a randomized clinical trial, use of recombinant and identical to the endogenous human SAP (PRM-151) was associated with reduction in fibrocytes in pulmonary fibrosis patients 34 . A Phase 2 study trial of PRM-151, a novel anti-fibrotic immunomodulator, was reported in patients with Idiopathic Pulmonary Fibrosis (IPF) 35 and in a 28-week Phase 2 trial, infusions of SAP improved lung function 36 , 37 by inhibiting alternative activation of macrophages and fibrocyte differentiation 31 , 32 .…”

Section: Introductionmentioning

confidence: 99%

Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus

et al. 2021

View full text Add to dashboard Cite

Serum amyloid P component (SAP, also known as Pentraxin 2; APCS gene) is a component of the humoral arm of innate immunity involved in resistance to bacterial infection and regulation of tissue remodeling. Here we investigate the role of SAP in antifungal resistance. Apcs−/− mice show enhanced susceptibility to A. fumigatus infection. Murine and human SAP bound conidia, activate the complement cascade and enhance phagocytosis by neutrophils. Apcs−/− mice are defective in vivo in terms of recruitment of neutrophils and phagocytosis in the lungs. Opsonic activity of SAP is dependent on the classical pathway of complement activation. In immunosuppressed mice, SAP administration protects hosts against A. fumigatus infection and death. In the context of a study of hematopoietic stem-cell transplantation, genetic variation in the human APCS gene is associated with susceptibility to invasive pulmonary aspergillosis. Thus, SAP is a fluid phase pattern recognition molecule essential for resistance against A. fumigatus.

show abstract

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study

Cited by 83 publications

References 11 publications

Deep learning in interstitial lung disease—how long until daily practice

Deep learning in interstitial lung disease—how long until daily practice

The Roles of Immune Cells in the Pathogenesis of Fibrosis

Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus

Contact Info

Product

Resources

About